Table 1.

Clinical profile for the patient population.

Pt n°	Sex	Age	Years since beginning	Type of seizures	Seizures frequency	Relevant history	Current antiepileptic therapy
1	M	19	15	Simple partial with SG	1–2/week (partial), 1–2/month (SG)	Negative	CLZ, OCX, LEV
2	F	41	17	Complex partial	2–3/day	Negative	ZNS, ESL, CLZ
3	M	31	15	Simple partial with SG	2/month, rare (SG)	Negative	LEV, LCM
4	M	23	14	Complex partial	2/day	Negative	VPA, TPM, LEV
5	M	32	8	Complex partial with SG	1–2/month	Negative	OCX, ZNS, VPA
6	F	49	42	Complex partial	2–3/week	Negative	VPA, CBZ, CLZ, ZNS
7	M	40	7	Complex partial	3/week	Negative	CBZ, LTG
8	F	25	12	Complex partial	3–4/day	Negative	LEV, CBZ, VPA, LCM
9	F	50	44	Complex partial	1/day	Negative	LEV, LCM
10	F	33	30	Complex partial	3–4/week	Negative	OCX, TPM, CLZ, CLP

Gender, age, seizures characteristics, and antiepileptic therapy are reported in table for each patient. In all cases, the electro-clinical diagnosis from the multi-disciplinary team reported a right temporal lobe epileptic focus. SG, secondary generalization; CLZ, Clobazam; OCX, Oxcarbazepine; LEV, Levetiracetam; ZNS, zonisamide; ESL, Eslicarbazepine; LCM, lacosamide; VPA, valproate; TPM, topiramate; CBZ, Carbamazepine; LTG, Lamotrigine; CLP, Clonazepam.